Zobrazeno 1 - 10
of 245
pro vyhledávání: ''
Autor:
Isabell Schulze, Zoe Quandt, Alexander Gusev, Melinda C. Aldrich, Andrew J. Plodkowski, Mohsen Abu-Akeel, Jia Luo, Taha Merghoub, Victoria Martucci, Jacklynn V. Egger, Donglei Hu, Hira Rizvi, Matthew A. Gubens, Scott Huntsman, Megan H. Murray, Christine M. Lovly, Matthew D. Hellmann, Elad Ziv, Min Li, Stefan Groha, Eduardo Cardenas
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 18
Purpose: Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly understood. We examined the genetics of thyroid immune-related adverse events (irAE).
Autor:
Karen Kelly, Everett E. Vokes, Jonathan W. Goldman, Rebecca S. Heist, Apurvasena Parikh, D. Ross Camidge, J. Wu, Minal A. Barve, Bruce A. Bach, Eric Angevin, Zhaowen Sun, David S. Hong, Philip Komarnitsky, John H. Strickler, Todd M. Bauer, Daniel Morgensztern, Monica Motwani
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules
Autor:
James H. Doroshow, Ting-Chia Chang, Sarah B. Miller, Jennifer Zlott, Lamin Juwara, Li Chen, Abdul Rafeh Naqash, Khanh T. Do, Geraldine O'Sullivan Coyne, Elad Sharon, Deborah Wilsker, Jiuping Ji, Alice P. Chen, Biswajit Das, Shivaani Kummar, Ashley Bruns, Larry Rubinstein, Ganesh Mugundu, Richard Piekarz, Arjun Mittra, Robert J. Kinders, Naoko Takebe, Howard Streicher, Ralph E. Parchment
Publikováno v:
Clin Cancer Res
Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report resul
Autor:
Hans-Peter Sinn, Ali Bashashati, Anna V. Tinker, Hans W. Nijman, Andreas D. Hartkopf, Felix K. F. Kommoss, Florian Heitz, Michael S. Anglesio, Derek S. Chiu, Lukas Feil, Emily F Thompson, Friedrich Kommoss, Mary Anne Brett, Martin Köbel, P Krämer, Aline Talhouk, Katherine Dixon, Bernhard K. Krämer, Sara Y. Brucker, Annette Staebler, Marco de Bruyn, Janine Senz, David Farnell, Naveena Singh, Philipp Harter, Zhouchunyang Xia, Daniëlla A Scheunhage, Tayyebeh M. Nazeran, Rory F L Hammond, M Grube, J Pasternak, H.-W. Vollert, Cornelis D. de Kroon, Sabine Heublein, Jessica N. McAlpine, Stefan Kommoss, Samuel Leung, Tjalling Bosse, Andreas du Bois, Ranjit Manchanda, Evan S. Cairns
Publikováno v:
Clinical Cancer Research, 26(20), 5400-5410. AMER ASSOC CANCER RESEARCH
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a “one-size-fits-all” approach. Even though
Autor:
Robert J. Motzer, Daniel J. George, Mariajose Lechuga, Michael Staehler, Bernard Escudier, Alain Ravaud, Xun Lin, Anup Patel, Jean-Francois Martini, Allan J. Pantuck
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Purpose: In the S-TRAC trial, adjuvant sunitinib improved disease-free survival (DFS) compared with placebo in patients with locoregional renal cell carcinoma (RCC) at high risk of recurrence. This post hoc exploratory analysis investigated the neutr
Autor:
David W. Markby, Rajesh Kaldate, Robin Kate Kelley, Joong-Won Park, Ghassan K. Abou-Alfa, Vincent C. Tam, Anthony B. El-Khoueiry, Philippe Merle, Thomas Yau, Stephen L. Chan, Ann-Lii Cheng, Lorenza Rimassa, Vincenzo Dadduzio, Jean-Frédéric Blanc, Tim Meyer, Albert Tran
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Purpose: The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes
Autor:
Michael J. LaRiviere, Elena Helman, Taylor A. Black, Wei-Ting Hwang, Rebecca J. Nagy, Theresa Christensen, Benjamin A. Silva, Katie Quinn, Charu Aggarwal, Austin L. Chien, Abigail T. Berman, Erica L. Carpenter, Joshua Bauml, Jeffrey C. Thompson, Corey J. Langer, Christine Ciunci, Kimberly C. Banks, Jeffrey S. Wasser, Stephanie S. Yee, Aditi P. Singh, Roger B. Cohen
Publikováno v:
Clin Cancer Res
Purpose: The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic non–small cell lung cancer (mNSCLC) has not been explored. Experimental Design: A 500-ge
Autor:
Daijing Yuan, Qing Lu, Hong Ma, Huamao Wang, Bo Zhai, Donghua Shi, Xingxing Qi, Yaoping Shi, Yuan Zhang, Hua Jiang, Huiping Gao, Hongyang Wang, Zonghai Li, Jiachang Chi, Ahmed Kaseb
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(15)
Purpose: Our preclinical studies demonstrated the potential of chimeric antigen receptor (CAR)-glypican-3 (GPC3) T-cell therapy for hepatocellular carcinoma (HCC). We report herein the first published results of CAR-GPC3 T-cell therapy for HCC. Patie
Autor:
Kristian Windfeld, Melissa Lynne Johnson, Yvette Drew, James Spicer, Robert H. Jones, Brian M. Slomovitz, Srinivas Ghatta, Nicole Concin, Nathalie Cornez, Hendrik Tobias Arkenau, Jeffrey R. Harris, Robert L. Coleman, Reshma A. Rangwala, Ignace Vergote, Martin Forster, Christine Gennigens, Ulrik Lassen, Jean Pascal Machiels, Johann S. de Bono, David S. Hong, Fiona C Thistlethwaite
Publikováno v:
Clinical cancer research, Vol. 26, no. 6, p. 1220-1228 (2020)
Hong, D S, Concin, N, Vergote, I, de Bono, J S, Slomovitz, B M, Drew, Y, Arkenau, H-T, Machiels, J-P, Spicer, J F, Jones, R, Forster, M D, Cornez, N, Gennigens, C, Johnson, M L, Thistlethwaite, F C, Rangwala, R A, Ghatta, S, Windfeld, K, Harris, J R, Lassen, U N & Coleman, R L 2020, ' Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer ', Clinical Cancer Research, vol. 26, no. 6, pp. 1220-1228 . https://doi.org/10.1158/1078-0432.CCR-19-2962
Hong, D S, Concin, N, Vergote, I, de Bono, J S, Slomovitz, B M, Drew, Y, Arkenau, H-T, Machiels, J-P, Spicer, J F, Jones, R, Forster, M D, Cornez, N, Gennigens, C, Johnson, M L, Thistlethwaite, F C, Rangwala, R A, Ghatta, S, Windfeld, K, Harris, J R, Lassen, U N & Coleman, R L 2020, ' Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer ', Clinical Cancer Research, vol. 26, no. 6, pp. 1220-1228 . https://doi.org/10.1158/1078-0432.CCR-19-2962
Background: Advanced recurrent or metastatic cervical cancer has a 5-year survival of only 17% and no current second-line standard-of-care, representing a significant unmet need. Tissue factor (TF) is a potential therapeutic target in cervical cancer
Autor:
Masato Kobayashi, Kiyoshi Ariizumi, Ponciano D. Cruz, Song Zhang, Vijay Ramani, Vinita Popat, Farjana J. Fattah, David E. Gerber, Jin Sung Chung
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(6)
Purpose: Immune checkpoint inhibitors (ICI) benefit only a minority of treated patients with cancer. Identification of biomarkers distinguishing responders and nonresponders will improve management of patients with cancer. Because the DC-HIL checkpoi